

RESEARCH ARTICLE

Characterization and Genetic Variation of *Vibrio cholerae* Isolated from Clinical and Environmental Sources in Thailand

Achiraya Siriphap¹, Pimlapas Leekitcharoenphon², Rolf S. Kaas², Chonchanok Theethakaew¹, Frank M. Aarestrup², Orasa Sutheinkul^{3*}, Rene S. Hendriksen^{2*}

1 Department of Microbiology, Faculty of Public Health, Mahidol University, Bangkok, Thailand, **2** National Food Institute, Technical University of Denmark, Research Group for Genomic Epidemiology, WHO Collaborating Center for Antimicrobial Resistance in Foodborne Pathogens and Genomics and European Union Reference Laboratory for Antimicrobial Resistance, Kgs. Lyngby, Denmark, **3** Faculty of Public Health, Thammasat University, Rangsit Center, Pathumthani, Thailand

* rshe@food.dtu.dk (RSH); orasa.s@fph.tu.ac.th, orasa.sut@maildol.ac.th (OS)



OPEN ACCESS

Citation: Siriphap A, Leekitcharoenphon P, Kaas RS, Theethakaew C, Aarestrup FM, Sutheinkul O, et al. (2017) Characterization and Genetic Variation of *Vibrio cholerae* Isolated from Clinical and Environmental Sources in Thailand. PLoS ONE 12 (1): e0169324. doi:10.1371/journal.pone.0169324

Editor: Ashlesh K Murthy, Midwestern University, UNITED STATES

Received: July 11, 2016

Accepted: December 15, 2016

Published: January 19, 2017

Copyright: © 2017 Siriphap et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All sequence data have been submitted to the European Nucleotide Archive under study accession number: PRJEB14630 (<http://www.ebi.ac.uk/ena/data/view/PRJEB14630>).

Funding: This work was supported in part by Department of Microbiology grant, the China Medical Board, the Faculty of Public Health of Mahidol University to Orasa Sutheinkul, the Danish Council for Strategic Research (grant number 09-067103) to Frank M. Aarestrup, and in part by the

Abstract

Cholera is still an important public health problem in several countries, including Thailand. In this study, a collection of clinical and environmental *V. cholerae* serogroup O1, O139, and non-O1/non-O139 strains originating from Thailand (1983 to 2013) was characterized to determine phenotypic and genotypic traits and to investigate the genetic relatedness. Using a combination of conventional methods and whole genome sequencing (WGS), 78 *V. cholerae* strains were identified. WGS was used to determine the serogroup, biotype, virulence, mobile genetic elements, and antimicrobial resistance genes using online bioinformatics tools. In addition, phenotypic antimicrobial resistance was determined by the minimal inhibitory concentration (MIC) test. The 78 *V. cholerae* strains belonged to the following serogroups O1: (n = 44), O139 (n = 16) and non-O1/non-O139 (n = 18). Interestingly, we found that the typical El Tor O1 strains were the major cause of clinical cholera during 1983–2000 with two Classical O1 strains detected in 2000. In 2004–2010, the El Tor variant strains revealed genotypes of the Classical biotype possessing either only *ctxB* or both *ctxB* and *rstR* while they harbored *tcpA* of the El Tor biotype. Thirty O1 and eleven O139 clinical strains carried CTX ϕ (Cholera toxin) and *tcpA* as well four different pathogenic islands (PAIs). Beside non-O1/non-O139, the O1 environmental strains also presented *chxA* and Type Three Secretion System (TTSS). The *in silico* MultiLocus Sequence Typing (MLST) discriminated the O1 and O139 clinical strains from other serogroups and environmental strains. ST69 was dominant in the clinical strains belonging to the 7th pandemic clone. Non-O1/non-O139 and environmental strains showed various novel STs indicating genetic variation. Multidrug-resistant (MDR) strains were observed and conferred resistance to ampicillin, azithromycin, nalidixic acid, sulfamethoxazole, tetracycline, and trimethoprim and harboured variants of the SXT elements.

For the first time since 1986, the presence of *V. cholerae* O1 Classical was reported causing cholera outbreaks in Thailand. In addition, we found that *V. cholerae* O1 El Tor variant and O139 were pre-dominating the pathogenic strains in Thailand. Using WGS and

World Health Organization Global Food-borne Infections Network and World Health Organization, Food Safety Office (WP-12-FOS-003342) to Rene S. Hendriksen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

bioinformatic tools to analyze both historical and contemporary *V. cholerae* circulating in Thailand provided a more detailed understanding of the *V. cholerae* epidemiology, which ultimately could be applied for control measures and management of cholera in Thailand.

Introduction

Vibrio cholerae is the causative agent of the severe, watery diarrheal disease cholera. *V. cholerae* is classified into approximately 206 serogroups of which O1 and O139 have the potential to cause cholera outbreaks and are associated with cholera pandemics. The remaining serogroups; determined non-O1/non-O139 are often referred to as environmental cholera [1–3] and part of the normal flora of aquatic ecosystems [4]. Nonetheless, some non-O1/non-O139 strains have the potential to cause mild diarrhea, and outbreaks have been observed in several countries including Thailand [5–7]. The serogroup O1 is divided into two biotypes: Classical and El Tor, based on phenotypic differences [2].

Since 1817, cholera has spread from the Indian sub-continent and seven pandemics have been observed, the seventh of which is still ongoing. The first six pandemics were associated with the O1 Classical biotype and ceased around 1923 [8, 9]. In 1961, the 7th pandemic began in Southeast Asia, caused by the O1 El Tor biotype [3, 10–13]. Whole genome sequence (WGS) analysis has identified eight distinct phylogenetic lineages: L1–L8 with L1 and L3–L6 representing the former pandemics and L2 the present 7th El Tor pandemic. Lineages L7 and L8 are formed by unique isolates [12]. The lineage L2 of the 7th pandemic has further been subdivided into three waves; I, II and III, of which, wave III seems to consist of several clusters [3, 12]. In general, the clusters separate isolates from Africa and India from those isolated in Haiti, Nepal, and Southeast Asia [12, 14]. In 1992, *V. cholerae* O139 emerged and caused epidemic cholera [15] followed in 2002 by the emergence of *V. cholerae* O1 variants; a genetic mixture of the Classical and El Tor biotypes. The *V. cholerae* O1 variants were later reported in several countries in Africa and Asia [16–19]. Since 2013, after the containment of the cholera outbreak in Haiti, the number of reported cholera cases has decreased globally. In Asia however, the incidence of cholera has increased and continues to pose a serious public health concern [20].

V. cholerae consists of two chromosomes and the hallmark of pathogenic *V. cholerae* is the major virulence factors; cholera toxin (CT) and toxin co-regulated pilus (TCP). The two virulence factors are clustered within two regions; the *Vibrio* pathogenicity island I (VPI-1) encoded by TCP [21] and the CTX genetic element comprised by a core region in CTX ϕ . The latter contains not only the genes of the cholera toxin, *ctxAB*, but also carries the zonular occludens toxin (*zot*) and accessory colonization enterotoxin (*ace*) [22]. In addition, other virulence genes encoding hemolysin (*hlyA*), heat stable enterotoxin (*stn*), mannose-sensitive hemagglutinin pilus (*mshA*), repeats-in-toxin A toxin (*rtxA*), and a ToxR regulatory protein (*toxR*) have been associated with diarrheal disease [23, 24]. Recently, the type III secretion system (TTSS) has been known as a key virulence factor and appears to be an important virulence factor for pathogenicity of non-O1/non-O139 [25].

Since 1997, endemic or sporadic cholera cases have been linked every year to contaminated seafood or potable water in Thailand [26]. Antimicrobial treatments have been recommended for only severe dehydration cases. Nonetheless, the occurrence of resistant strains has dramatically increased [27]. The presence of the SXT element and class I integron have been reported to contribute to the spread of antimicrobial resistance genes among *V. cholerae* and other bacteria [28].

The objective of this study was to provide more knowledge of the genotypic variation in *V. cholerae* observed during the past three decades in Thailand. A collection of clinical and environmental *V. cholerae* serogroup O1, O139, and non-O1/non-O139 strains collected between 1983 and 2013 in Thailand were characterized by a combination of conventional microbiological tests, molecular methods, next generation sequencing, and bioinformatics tools to determine the pheno- and genotypes. In addition, the distribution of virulence-associated genes and the occurrence of antimicrobial resistance and corresponding resistance genes including the class 1 integron and SXT element among *V. cholerae* strains were subsequently analyzed to elucidate the emerging antimicrobial resistance and virulence properties.

Materials and Methods

Bacterial strains

A total of 78 *V. cholerae* strains were selected for this study based on the serogroups O1, O139, and non-O1/non-O139, the sources for these strains were the clinic and environment, and date (1983–2013) from the culture collection of the Department of Microbiology, Faculty of Public Health, Mahidol University, Thailand (Table A in [S1 File](#)). The clinical strains were previously isolated from stools and rectal swabs of patients suffering from sporadic cases or outbreaks of cholera in central Thailand and the environmental strains were isolated from seafood, water, and hand swabs.

Characterization of *V. cholerae*

The purity of all *V. cholerae* strains were assessed on Thiosulfate-citrate-bile salts-sucrose (TCBS) agar prior to confirmation using a combination of biochemical, serological, and molecular methods as previously described [29, 30]. Serogroups and serotypes were determined by slide agglutination utilizing specific polyvalent antisera against *V. cholerae* O1 and O139, and monovalent specific to Inaba and Ogawa antisera (S & A Reagents Lab, Bangkok, Thailand) and by touchdown-multiplex polymerase chain reaction (TMPCR) using species-specific primers for *V. cholerae* (*ompW* gene) and serogroup-specific for O1 (*rfbV* gene) and O139 (*wbfZ* gene) [30].

All *V. cholerae* O1 strains were classified according to biotypes using the quality control strains; O395 (O1 Classical), N16961 (O1 El Tor), and MO45 (O139) and based on the combination of previously described conventional biotyping methods [31] and genotypically by a bioinformatics tool: MyDbFinder (<https://cge.cbs.dtu.dk/services/MyDbFinder/>) as previously described [32].

Antimicrobial susceptibility testing

Antimicrobial susceptibility to ampicillin (AMP), azithromycin (AZM), cefotaxime (CTX), chloramphenicol (CHL), ciprofloxacin (CIP), gentamicin (GEN), meropenem (MEM), nalidixic acid (NAL), sulfamethoxazole (SMX), ceftazidime (CAZ), tetracycline (TET), tigecycline (TGC), and trimethoprim (TMP) was performed by broth microdilution to determine minimum inhibitory concentration (MIC) with a commercially prepared, panel of dehydrated antimicrobials (Sensititre; TREK Diagnostic Systems Ltd., East Grinstead, England). Antimicrobial susceptibility test results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) breakpoints [33], except for tigecycline, for which the clinical breakpoint was used according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations (<http://www.eucast.org>). *Escherichia coli* ATCC 25922 was used as reference strain for quality control according to CLSI guidelines [33].

Whole genome sequencing

V. cholerae genomic DNA was extracted using the Invitrogen Easy-DNA™ Kit (Invitrogen, Carlsbad, CA, USA). The concentrations of the extracted DNA were determined using a Qubit dsDNA BR assay kit (Invitrogen). The genomic DNA was prepared for Illumina paired-end sequencing using the Illumina (Illumina, Inc., San Diego, CA) NexteraXT® Guide 150319425031942 following protocol revision C. A sample of pooled NexteraXT Libraries was loaded onto an Illumina MiSeq reagent cartridge using MiSeq Reagent Kit v2 and 500 cycles with a Standard Flow Cell. The libraries were sequenced using the MiSeq Illumina platform and MiSeq Control Software 2.3.0.3. All strains were paired-end sequenced.

Raw sequence data were submitted to the European Nucleotide Archive (<http://www.ebi.ac.uk/ena>) under study accession no.: PRJEB14630 (<http://www.ebi.ac.uk/ena/data/view/PRJEB14630>). The raw reads were assembled using the Assemble pipeline (version 1.0) available from the Center for Genomic Epidemiology (CGE; <http://cge.cbs.dtu.dk/services/all.php>) based on the Velvet algorithms for *de novo* short reads assembly. A complete list of genomic sequence data is available in Table B in [S1 File](#).

The use of bioinformatics tools

Identification of *V. cholerae* and determination of associated virulence genes and pathogenicity islands. MyDbFinder is a BLAST-based search-engine that was developed as “an empty database” in the same format as the ResFinder tool [34] to identify user-defined genes (<https://cge.cbs.dtu.dk/services/MyDbFinder/>). The users populate their own database by including DNA sequences of interest in FASTA format into a pure text file. MyDbFinder query raw reads or assembled genome data and outputs the best matching genes from the user’s database.

The web-server MyDbFinder 1.0 was used to, *in silico*, determine the species-specific gene (*ompW*), serogroup-specific genes (*rfbV*-O1, *wbfZ*-O139), biotypes-specific genes (*ctxB*, *rstR*, *tcpA*), specific gene (VC2346) of the 7th pandemic strain, putative virulence genes (*ctxA*, *ctxB*, *zot*, *ace*, *tcpA*, *hlyA*, *stn*, *chxA*, *rtxA*, *ompU*, *toxR*, *mshA*, TTSS), and pathogenic islands (PAI): (VPI-1, VPI-2, VSP-1, VSP-2) in all *V. cholerae* strains with a selected threshold equal to 95% identity as previously described [32]. The genes used in this study are shown in Table C in [S1 File](#).

Determination of antimicrobial resistance genes, SXT element, and class 1 integron.

In all *V. cholerae* strains, antimicrobial resistance genes were detected based on the assembled sequences using the ResFinder tool (version 2.1, 80% threshold for %ID/ 60% minimum length) available from CGE [34]. The SXT element, class 1 integron, and presence of mutation in the DNA gyrase gene (*gyrA*), and the DNA topoisomerase IV genes (*parC* and *parE*) were determined using MyDbFinder as previously described [32]. The nucleotide sequence of integrase gene of the SXT element (*int_{SXT}*), the class 1 integron (*intI*), *gyrA*, *parC*, and *parE* genes of the quinolone-resistant *V. cholerae* strains from GenBank were used as references (Table C in [S1 File](#)).

ICEVcHai1 (JN648379) and *dfrA18* gene of SXT^{MO10} (AY034138) were used as templates in MyDBFinder (threshold, 95% identity) to determine which *V. cholerae* strains contained an *int_{SXT}* gene.

Multilocus sequence type. The assembled sequences were analyzed to identify the MLST, sequence type (ST) for *V. cholerae* using the MLST tool (version 1.7) available from CGE [35]. The seven housekeeping genes: *adk*, *gyrB*, *metE*, *mdh*, *pntA*, *purM*, and *pyrC* as previously described by Octavia *et al.* (2013) [36], were extracted from 78 *V. cholerae* genomes in this study and 6 *V. cholerae* genomes from the NCBI database (M66-2, O395, N16961, MO45,

MS6, 2010EL-1786). Concatenation of the housekeeping gene sequences was performed with an in-house python script. A multiple alignment was created from the concatenated sequences using MUSCLE via MEGA5 [37]. The final phylogenetic MLST tree was constructed by MEGA5 using the maximum likelihood method of 1,000 bootstrap replicates using Tamura-Nei model for inference [38]. Figtree (<http://tree.bio.ed.ac.uk/software/figtree/>) was used to visualize the tree. The confidence of the nodes in the tree is estimated by bootstrap values, calculated by sampling with replacements from the multiple sequence alignment. New STs were confirmed by PCR as previously described Octavia *et al.* (2013) [36].

Genomic islands in the chromosomes of *V. cholerae*. Variation of genomic islands including CTX, VPI-1, VPI-2, VSP-1, VSP-2, and the super-integron were visualized and determined based on chromosome I and II of the reference genome *V. cholerae* N16961 (accession no. AE003852 and AE003853) using a BLAST atlas. All protein sequences from the reference genome were aligned against other *V. cholerae* genomes using BLASTP. The presence and absence of genes were visualized in a circle, with greater similarity represented by higher intensity of color [39].

Results

Characterization of *V. cholerae* strains

Of the 78 *V. cholerae* strains investigated, 44 belonged to serogroup O1, 16 to O139, and 18 to non-O139/non-O1. Among the 44 *V. cholerae* O1 strains, 24 strains were identified as Inaba and 20 strains as Ogawa (Fig 1, Table D in S1 File).

The biotype classification of the 44 *V. cholerae* O1 strains revealed 15 strains determined as being typical El Tor similar to the phenotype of El Tor strain N16961 (CCA⁺ HSE⁺ PB^r VP⁺). The 15 strains all carried according to MyDbFinder identical genes; *ctxB*, *rstR*, and *tcpA* with the exception of three environmental strains (TC22, MK14, and 4T5) and one clinical strain (TC183). Two strains (VC O1-8 and VC O1-10) belonged to the biotype Classical, exhibiting the phenotype CCA⁻ HSE⁻ PB^s VP⁻ and genotypically similar to O395 strain (Classical). Furthermore, 26 *V. cholerae* O1 strains tested phenotypically El Tor but revealed using MyDbFinder mixed Classical and El Tor genotypes and determined as an El Tor variant. Finally, one *V. cholerae* O1 strain (MK14) expressed phenotypically both biotypes (CCA⁺ HSE⁺ PB^s VP⁺) and was determined as belonging to the hybrid biotype (Fig 1, Table D in S1 File).

The MLST types of the 78 *V. cholerae* and 6 reference genomes were analyzed and assigned to 26 different STs (Fig 1). The analysis showed that 50 strains were represented by ST69, making this the most common ST and all 50 of these strains related to clinical strains. Among clinical strains, 38 O1 El Tor and 12 serogroup O139 belonged to the same cluster with the pandemic strains (N16961 and MO45) and the Haitian strain (2010EL1786). The strains harbored the 7th pandemic-specific gene (VC2346) according to MyDbFinder, suggesting that they belong to the same clonal lineage. The cluster is also linked to the pre-6th pandemic strain (M66-2) and the endemic strain from Thailand (MS6), which was closely related to the cluster of the O1 Classical strains (ST73) including the strains related to the 6th pandemic (Table E in S1 File). All of the non-O1/non-O139 strains and the environmental strains, except for four O139 strains belonging to ST187, were assigned to different novel STs, suggesting a high degree of genetic diversity.

Distribution of virulence-associated genes and pathogenicity islands

The distribution of virulence-associated genes and pathogenicity islands among the 78 *V. cholerae* strains was determined using MyDbFinder (Fig 1 and Table 1). All strains harbored the virulence-associated genes *hlyA*, *rtxA*, and *toxR*, with only the *stn* gene absent. Ten of the 17

Table 1. Occurrence of virulence-associated genes among *Vibrio cholerae* strains from Thailand.

Serogroup	Source	No. (%) of strains											
		<i>ctxA</i>	<i>ctxB</i>	<i>zot</i>	<i>ace</i>	<i>tcpA</i>	<i>hlyA</i>	<i>mshA</i>	<i>rtxA</i>	<i>ompU</i>	<i>toxR</i>	<i>chxA</i>	TTSS ^a
O1	Clinical	30	29	30	30	39	40	40	40	40	40	0	0
	(n = 40)	(75.0)	(72.5)	(75.0)	(75.0)	(97.5)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)		
O139	Environmental	0	0	0	0	0	4	3	4	2	4	1	1
	(n = 4)						(100.0)	(75.0)	(100.0)	(50.0)	(100.0)	(25.0)	(25.0)
non-O1/non-O139	Clinical	11	6	9	11	12	12	12	12	12	12	0	0
	(n = 12)	(91.7)	(50.0)	(75.0)	(91.7)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)	(100.0)		
non-O1/non-O139	Environmental	0	0	0	0	0	4	0	4	4	4	0	0
	(n = 4)						(100.0)		(100.0)	(100.0)	(100.0)		
Total (n = 78)	Clinical	0	0	0	0	0	2	1	2	0	2	0	1
	(n = 2)						(100.0)	(50.0)	(100.0)		(100.0)		(50.0)
Total (n = 78)	Environmental	0	0	0	0	0	16	3	16	2	16	3	0
	(n = 16)						(100.0)	(18.8)	(100.0)	(12.5)	(100.0)	(18.8)	
Total (n = 78)		41	35	39	41	51	78	59	78	60	78	4	2
		(52.6)	(44.9)	(50.0)	(52.6)	(65.4)	(100.0)	(75.6)	(100.0)	(76.9)	(100.0)	(5.1)	(2.6)

All *V. cholerae* strains lacked *stn* gene.

^a Positive all four genes: *vcsC2*, *vcsN2*, *vcsV2*, and *vspD*

doi:10.1371/journal.pone.0169324.t001

virulence-associated genes (*ctxA*, *ctxB*, *zot*, *ace*, *tcpA*, *hlyA*, *mshA*, *rtxA*, *ompU*, and *toxR*) were found in 34 of the clinical strains (serogroup O1 and O139). Moreover, these strains contained the pathogenicity islands (PAIs) VPI-1, VPI-2, VSP-1, and VSP-2, except for two strains of O139 (6668/3 and 6225/3), which lacked VSP-2. All non-O1/non-O139 strains obtained from a clinical source harbored the *hlyA*, *rtxA*, and *toxR* genes, whereas strain IPD1231/8 52B in addition also harbored the *mshA*, TTSS, and VPI-2. Two out of four O1 strains of environmental origin harbored *hlyA*, *mshA*, *rtxA*, *ompU*, *toxR*, and VPI-2. Only one O1 strain contained the genes *chxA* (TC 22), TTSS (MK14), and VSP-1 (MK14). Among environmental strains, the virulence-associated genes and the PAIs of the non-O1/non-O139 similar to the O1 strain were detected but lacked TTSS and VSP-1. All four O139 strains harbored *hlyA*, *rtxA*, *ompU*, *toxR*, and VPI-2. Nine *V. cholerae* genomes based on the different serogroups, biotypes, and sources were compared using a BLAST atlas. The atlas revealed several variable genomic regions in chromosome I (Fig 2A) and II (Fig 2B). VPI-1, VPI-2, VSP-1, and VSP-2 were determined in the chromosome I among the regions of PAIs including CTX ϕ , especially the clinical strains of O1 El Tor (510/77, 22116, P25), and O139 (22136). The O1 Classical (VC O1-8) and non-O1/non-O139 (IPD221/8 44B) strain lacked VSP-1 and VSP-2. Among the environmental strains, the O1 strain (MK14) harbored two PAIs, VSP-1 and VPI-2, while both O139 (DT8) and non-O1/non-O139 strains (VCR12) harbored only VPI-2. A large genomic island, super-integron, located in the chromosome II, showed more genetic diversity and obviously differed among these strains.

Antimicrobial resistant strains, antimicrobial resistance genes, class 1 integron, and SXT element

The MIC determination of all 78 *V. cholerae* strains revealed that 48 of them originating between 1991 and 2013 were resistant to at least one antimicrobial (Table 2). The 48 strains were resistant to TMP (52.6%), SMX (48.7%), NAL (43.6%), TET (14.1%), AMP (7.7%), and AZM (6.4%). Moreover, 27 (56.3%) of the 48 antimicrobial resistant strains were considered multidrug




Fig 2. Genomic variation of representative *Vibrio cholerae* strains in Thailand. BLAST atlas with chromosome I (A) and II (B) of *V. cholerae* N16961 as reference strain (black) followed by the nine representative strains of serogroup O1, O139, and non-O1/non-O139 composed of serogroup O1 (blue) (clinical strains: 510/77, typical El Tor; VCO1-8, classical; 22116 and P25, El Tor variant; environmental strain: MK14, hybrid El Tor), O139 (green) (clinical strains: 22136, environmental strain: DT8), and non-O1/non-O139 (red) (clinical strains: IPD221/8 44B, environmental strain: VCR12).

doi:10.1371/journal.pone.0169324.g002

resistant (MDR) and conferred resistance to three or more antimicrobial classes and exhibited four distinct MDR patterns: NAL-SMX-TMP, NAL-TET-TMP, NAL-SMX-TET-TMP, and AZM-NAL-SMX-TET-TMP (Table F in S1 File). It is noteworthy to mention that some resistance genes were observed among the strains being phenotypically susceptible. These strains were of O1, O139, and non-O1/non-O139, isolated between 1983 and 2010 and harbored the *catB9* (60.3%) and *floR* (35.9%) conferring resistance to chloramphenicol (O-acetyltransferase activity) and florfenicol (co-resistance to both chloramphenicol and florfenicol), respectively.

The presence of the specific integrase genes of class 1 integron (*intI* gene) and SXT element (*intS_{SXT}* gene) were *in silico* determined among the 78 *V. cholerae* strains using MyDbFinder (Table 3). All of the strains lacked the *intI* gene. In contrast, 43 strains of *V. cholerae* serogroups O1, O139, and non-O1/non-O139 isolated during 1991 to 2013 presented the *intS_{SXT}*. The SXT element harbored the following antimicrobial resistance genes: *sul2*, *dfrA1*, *dfr18*, *floR*, *strA*, and *strB*, which are mostly associated with SMX and TMP resistant strains (Fig 3).

The majority of *V. cholerae* strains (52.6%) were resistant to TMP, of which strains belonging to serogroup O1 (2001–2005) contained the *dfrA1* gene and O139 strains (1991–2000) contained the *dfrA18* gene (Table 3). All 38 (48.7%) strains conferring resistance to SMX contained *sul2* gene. Among the six AMP-resistant strains (7.7%), four O139 environmental strains (DT8, DT7, WKB T9, and PKN T5) and one clinical non-O1/non-O139 strain (1231/8 52B) harbored the *bla_{P1}* and the *bla_{CARB-9}* gene, respectively, whereas only one non-O1/non-O139 environmental strain (I-WASTE-HSH1-TY2) harbored the *bla_{CARB-7}* gene. All five clinical O1 strains (6.4%) resistant to AZT contained the *mphA* gene. Interestingly, the 11 strains resistant to TET lacked resistance genes. The genes *strA* and *strB* conferring resistance to streptomycin were present in 39 strains (50%) including 12 strains (100%) of O139 and 1 strain (25%) of non-O1/non-O139 isolated during 1991–2000.

Amino acid substitutions in codon *gyrA* (Ser83Ile) and *parC* (Ser85Leu) were observed in 34 NAL-resistant strains (43.6%) isolated between 1991 and 2013 belonging to serogroup O1, O139, and non-O1/non-O139. In addition, one non-O1/non-O139 strain (1262 W278) conferred resistance to quinolone harboring the *qnrVC5*.

The whole genome sequence of the strains harboring the SXT element revealed a structure organized similar to ICE*Vch*Hai1 and SXT^{MO10} in the GenBank (Fig 3). Most strains except

Table 2. Frequency of resistance of *Vibrio cholerae* strains in Thailand.

Variable	Serogroup	No. of strains	No. (%) of resistant strains	No. (%) of strains resistant to various antimicrobial agents indicated CLSI clinical breakpoints values (µg/ml)					
				AMP	AZM	NAL	SMX	TET	TMP
				≥32	>2	≥32	≥512	≥16	≥4
Year:									
1983–1990	O1	7	0	0	0	0	0	0	0
	non	2	0	0	0	0	0	0	0
1991–2000	O1	3	0	0	0	0	0	0	0
	O139	12	12 (100.0)	0	0	0	12 (100.0)	0	12 (100.0)
	non	4	3 (75.0)	1 (25.0)	0	2 (50.0)	0	1 (25.0)	2 (50.0)
2001–2010	O1	32	27 (84.4)	0	5 (15.6)	27 (84.4)	26 (81.3)	10 (31.3)	27 (84.4)
	non	5	1 (20.0)	0	0	1 (20.0)	0	0	0
2011–2013	O1	2	0	0	0	0	0	0	0
	O139	4	4 (100.0)	4 (100.0)	0	4 (100.0)	0	0	0
	non	7	1 (14.3)	1 (14.3)	0	0	0	0	0
Source:									
Clinical		54	40 (74.1)	1 (1.9)	5 (9.3)	27 (50.0)	38 (70.4)	10 (18.5)	39 (72.2)
Environmental		24	8 (33.3)	5 (20.8)	0	7 (29.2)	0	1 (4.2)	2 (8.3)
Total		78	48 (61.5)	6 (7.7)	5 (6.4)	34 (43.6)	38 (48.7)	11 (14.1)	41 (52.6)

Abbreviations: AMP, ampicillin; AZM, azithromycin; NAL, nalidixic acid; SMX, sulfamethoxazole; TET, tetracycline; TMP, trimethoprim; non, non-O1/non-O139. No resistance observed for cefotaxime (R ≥ 4 µg/ml), ceftazidime (R ≥ 16 µg/ml), chloramphenicol (R ≥ 32 µg/ml), ciprofloxacin (R ≥ 4 µg/ml), gentamicin (R ≥ 16 µg/ml), meropenem (R ≥ 16 µg/ml), and tigecycline (R > 2 µg/ml) (tigecycline was interpreted according to EUCAST based on clinical breakpoint).

doi:10.1371/journal.pone.0169324.t002

for 4053024303, 4053024306, and 22138 shared the similar structures of SXT element with common known deletions in loci VC1786ICE6 and VC1786ICE14. The variations in the SXT structures separated the individual serogroup O1, O139, and non-O1/non-O139 into distinct branches of the phylogenetic tree (Fig 3). The SXT elements of O1 strains were divided into two clades (GI and GII). The SXT structure of GI was highly similar to the structure of ICEVchHai1. Nineteen loci including *dfrA18* and *floR* were absent in GII. The SXT structures among the O139 strains harbored loci similar to SXT^{MO10} and ICEVchHai1 but lacked 25 loci including *dfrA1*. For non-O1/non-O139 strains, four strains harbored the SXT element and their SXT structures were similar to those of O139 strains. Only one resistant strain, VHS1-22I, harbored *floR*, *strA*, *strB*, and *sul2* genes. Two susceptible strains and one NAL-resistant strain did not contain these antimicrobial resistance genes including *dfrA18* and *dfrA1*.

Discussion

Since 1982, *V. cholerae* has been present and emerging in Thailand [40]. In the last decade, sporadic cholera cases have been observed in Thailand caused primarily by *V. cholerae* O1 and O139. In this study, we found that the phenotypic results characterizing *V. cholerae* were all in concordance with the *in silico* genotypic data revealed by WGS targeting the following genes: *ompW*, *rfbV*, *wbfZ*, *ctxB*, *rstR*, and *tcpA*. These genes have previously been used to classify *V. cholerae* strains [27, 30, 41–43]. The tested strains were classified into serogroups O1, O139, and non-O1/non-O139 showing that both *V. cholerae* serogroup O1 and O139 are present in Thailand and have potentially caused cholera.

In Thailand, several studies have reported the emergence of *V. cholerae* however, the bio-type *V. cholerae* O1 classical has not been detected since 1986 [27, 44–46]. Interestingly, this

Table 3. Frequency of SXT element and antimicrobial resistance genes in *Vibrio cholerae* strains, Thailand.

Year	Serogroup	SXT	No. (%) of strains													
			Aminoglycoside			Beta-lactam		Phenicol		Sulphonamide		Trimethoprim		MLS	Quinolone	
			<i>strA</i>	<i>strB</i>	<i>blaP1</i>	<i>blaCARB-7</i>	<i>blaCARB-9</i>	<i>catB9</i>	<i>ficR</i>	<i>su12</i>	<i>dfrA1</i>	<i>dfrA18</i>	<i>mph(A)</i>	<i>qnrVC5</i>	<i>GyrA(S83I)</i>	<i>ParC(S85L)</i>
1983–1990	O1	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0
								(28.6)								
1991–2000	non-O1/non-O139	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
														(50.0)		
2001–2010	O139	12	12	12	0	0	0	12	12	12	0	12	0	0	0	0
		(100.0)	(100.0)	(100.0)				(100.0)	(100.0)	(100.0)		(100.0)				
2001–2010	non-O1/non-O139	1	1	1	0	1	1	2	1	1	0	0	0	0	0	2
		(25.0)	(25.0)	(25.0)		(25.0)	(25.0)	(50.0)	(25.0)	(25.0)						(50.0)
2001–2010	O1	27	26	26	0	0	0	28	15	26	27	0	6	0	0	27
		(84.4)	(81.3)	(81.3)				(87.5)	(46.9)	(81.3)	(84.4)		(18.8)			(84.4)
2001–2010	non-O1/non-O139	2	0	0	0	0	0	2	0	0	0	0	0	0	1	1
		(40.0)						(40.0)							(20.0)	(10.0)
2011–2013	O1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2011–2013	O139	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4
																(100.0)
2011–2013	non-O1/non-O139	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
		(14.3)			(14.3)											
Total	Total	43	39	39	5	1	5	47	28	39	27	12	6	1	34	
		(55.1)	(50.0)	(50.0)	(6.4)	(1.3)	(6.4)	(60.3)	(35.9)	(50.0)	(34.6)	(15.4)	(7.7)	(1.3)	(43.6)	

Abbreviations: MLS, macrolide-lincosamide-streptogramin

doi:10.1371/journal.pone.0169324.t003




Fig 3. Genetic variation of SXT element in *Vibrio cholerae*. The SXT structures of among 43 *V. cholerae* strains from Thailand were compared. Reads were mapped to genes of ICE Vc-Hai1 (accession no. JN648379) and *dfrA18* gene in SXTMO10 element (accession no. AY034138).

doi:10.1371/journal.pone.0169324.g003

study revealed that two strains obtained from stool samples in 2000 were identified as the Classical biotype and were genetically similar to the strains related to the 6th cholera pandemic (Table E in S1 File). This indicated that the Classical biotype might have re-emerged, causing cholera outbreaks in Thailand after having been absent for several years during the 6th cholera pandemic. The decline of typical El Tor strains coincided with the first reports from Bangladesh of the emergence of the El Tor variant strain [16]. Furthermore, the El Tor variants possessing both the Classical and El Tor biotypes were recovered from clinical strains during 2004–2010. Detection of the El Tor variant was previously reported in Cameroon, India, and Thailand [18, 32, 41]. The variant of the Classical and El Tor biotypes increases the severity of the disease and may result in higher morbidity and mortality [47, 48]. Kim *et al.* suggested that the El Tor variant possessing the Classical biotype originated through recombination between the Classical and El Tor types of CTX ϕ [49]. One hybrid strain of this study, MK14, originating from a river water sample, lacked the biotype-specific genes as well as the main virulence genes (*ctxAB* and *tcpA*), suggesting it to be a non-toxigenic strain and in agreement with previous reports [50, 51]. The non-toxigenic strains, however, have been responsible for causing mild to moderate diarrhea in human volunteers in clinical trials [2]. These El Tor variant strains clustered together with the clinical strains including typical El Tor biotype and O139 serogroup. Moreover, the *in silico* MLST analysis showed that the clinical strains had a highly genetic relationship with the pandemic and outbreak strains. The majority of the clinical strains O1 and

O139 belonged to ST69 and showed genetic similarity to the 7th pandemic strain (N16961), the Haitian outbreak strain (2010EL-1786), and the Cameroon outbreak strains [32]. In addition, all of the clinical strains harbor the specific gene marker of the 7th pandemic clone. These findings suggest that the clinical strains (1983–2010) in Thailand might originate from a common ancestor of the 7th pandemic strain. The STs of the clinical strains showed that they were closely related to the pre 6th pandemic strain (M66-2) and a previous outbreak strain in Thailand (MS6) [52]. The clinical strains of O1 and O139 were highly conserved with regard to MLST (ST69) but contained different virulence genes, particularly *ctxAB* and *tcpA*. These findings have previously been reported and might be a result of horizontal gene transfer [36, 53, 54]. The *in silico* MLST analysis clearly showed discrimination amongst the different sources (clinical and environmental) and serogroups O1 and O139 as compared with non-O1/non-O139 strains. The clinical strains of O1 and O139 were highly conserved with regard to MLST (ST69), while the environmental strains of O1, O139, and non-O1/non-O139 and the clinical strains of non-O1/non-O139 revealed different and novel STs. This indicates that the environmental strains including non-O1/non-O139 were highly diverse; however, these results might be caused by gene recombination and/or mutation [36].

Furthermore, the environmental strains could be distinguished from the clinical strains using *in silico* MLST based on the difference in the virulence gene profiles. The environmental strains of O1 and O139 lacked the CTX ϕ and *tcpA* genes, especially. However, these strains harbored other virulence genes similar to non-O1/non-O139. Both *chxA* and TTSS genes were frequently found among non-O1/non-O139 pathogenic strains and associated with diarrhea [36, 51, 55]. However, the environmental O1 strains in this study harbored *chxA* gene (TC22) and TTSS (MK14), indicating virulence potential to cause disease.

Our study showed that the antimicrobial resistance profiles SMX-TMP and NAL-SMX-TMP were predominant among the clinical strains of serogroup O139 and O1, respectively. In addition, other clinical strains exhibited resistance to TET, AZM, and AMP in contrast to the environmental strains which were mostly resistant to NAL followed by AMP, TMP, and TET. Previous reports have described different antimicrobial resistant profiles compared with those from Thailand, such as resistance to furazolidone, NAL, sulfisoxazole, streptomycin, and trimethoprim/sulfamethoxazole in Haiti [56] as well as TET, streptomycin, sulfisoxazole and trimethoprim in China [57]. During 2003–2011, *V. cholerae* O1 has been reported as being resistant to erythromycin, TET, trimethoprim/sulfamethoxazole, and AMP in Thailand [27].

Our study showed a similar concordance between the antimicrobial susceptibility testing data and the *in silico*-detected corresponding resistance genes in the *V. cholerae* strains using the ResFinder bioinformatics tool [34]. A few disagreements were observed and confirmed by re-testing the MIC determination. These discrepancies related to TET-resistant strains in which no conferring resistance genes or other resistance mechanisms could be detected. This phenomenon is well-known and has previously been reported related to potential efflux pumps [58]. In contrast, we observed some strains that harbored both *floR* and *catB9* but displayed a susceptible phenotypic resistance profile. This observation has also been described in a recent publication describing the cholera in Haiti [56]. Similarly, susceptible non-O1/non-O139 strains harboring the *qnrVC5* gene did not express resistance to quinolone. Normally, one would anticipate isolates that harbor the genes *floR* and *catB9* would be associated with reduced susceptibility to CHL [59] and those that harbor the gene *qnrVC5* would be associated with quinolone resistance. These abnormalities are most likely linked to incorrect interpretative criterion.

According to World Health Organization (WHO) recommendations, TET and CIP are the drugs of choice for the treatment of cholera. Unfortunately, there is a lack of prudent usage in Thailand because these antimicrobials are being misused/overused in the agricultural section [60]. During 2003–2011, the endemic cholera strains in Thailand were resistant to TET,

whereas cholera was still susceptible to CIP as proven by Chomvarin *et al.*, 2013 [27] and in this study. Amino acid substitutions in *gyrA* and *parC* are the main mechanism responsible for quinolone resistance in *V. cholerae* [56, 58, 61]. In this study, the same point mutations in *gyrA* (S83I) and *parC* (S85L) were detected among NAL-resistant strains found in both clinical and environmental sources.

The SXT element is an ICE that translocates a panel of antimicrobial resistance genes via horizontal gene transfer [62]. The first SXT, SXT^{MO10}, was discovered in *V. cholerae* O139 strain MO10. It harbored resistant determinants to trimethoprim (*dfrA18*), streptomycin (*strA*, *strB*), sulfamethoxazole (*sul2*), and chloramphenicol (*floR*) [63]. Other ICEs identified in O1 and non-O1/non-O139 harbor a similar set of resistance genes as the SXT^{MO10} strain [28, 64]. Recently, WGS has been used to identify a variant of SXT in a Haitian O1 strain, ICE*Vch*-Hai1 harboring *dfrA1*, *strA*, *strB*, *sul2*, and *floR* [56]. We analyzed the genetic variation in SXT elements by comparing with gene loci in ICE*Vch*Hai1 and *dfrA18* in SXT^{MO10}. ICE*Vch*Hai1 has previously been used as the reference for comparison with the SXT element in India [64]. In this study, we found that the SXT in each of the different serogroups O1, O139, and non-O1/non-O139 were distinctly different. The SXT structures of the O1 strains showed a higher genetic similarity with ICE*Vch*Hai1 than the SXT structures of O139 and non-O1/non-O139 strains. This indicated that the acquired SXT element in the O1 Thai strains were similar to those of the Haitian and Indian strains. These findings are consistent with a previous study that showed identity of SXT within the same serogroup of *V. cholerae* [28].

In this study, we found that the re-occurrence of classical toxigenic strains have been persisted since 2000 in Thailand. The variation of phenotypic and genotypic characteristics shows that the *V. cholerae* O1 biotype El Tor variant has caused the majority of the outbreaks since 2004. The *V. cholerae* O1 and O139 obtained from clinical source commonly harboured CTX ϕ and *tcpA*. Conversely, their environmental strains lacking those virulence genes could be detected. Moreover, the occurrence of SXT element and resistance genes conferring antimicrobial resistance was encountered among Thai strains. These findings suggest that lysogenicity of *V. cholerae* O1 for CTX ϕ and other genetic markers including resistance genes should be further intensively surveillance and control. Future application of WGS combined with bioinformatic tools, such as MLST [35], MyDbFinder, ResFinder [34], and VcTypeFinder (in development), have in this study proven the power and are highly discriminatory methods in understanding the epidemiology of *V. cholerae*.

Conclusions

In this study, we used WGS and bioinformatic tools to analyze both historical and contemporary *V. cholerae* circulating in Thailand. To our knowledge, this is the first time since 1986 that the presence of *V. cholerae* O1 classical has been reported causing cholera outbreaks in Thailand. We found that the majority of the pathogenic strains belonged to *V. cholerae* O1 El Tor variant and O139. *In silico* analysis showed that the clinical strains shared common genetic background as well as harbored virulence genes, PAIs and mobile genetic elements associated with antimicrobial resistance while environmental strains were highly diverse. This study contributed to understanding the epidemiology of *V. cholerae* in Thailand that ultimately can be applied for control measures and management of the disease in Thailand.

Supporting Information

S1 File. Supplementary_table1-Sequence_info.
(XLS)

Author Contributions

Conceptualization: OS CT RSH FMA.

Data curation: PL.

Formal analysis: AS PL.

Funding acquisition: FMA OS RSH.

Investigation: AS RSH PL.

Methodology: RSH PL AS RSK.

Project administration: RSH.

Resources: FMA.

Software: AS PL RSK.

Supervision: RSH OS CT PL.

Validation: RSH OS.

Visualization: AS PL.

Writing – original draft: AS.

Writing – review & editing: RSH PL.

References

1. Bhattacharya SK, Bhattacharya MK, Nair GB, Dutta D, Deb A, Ramamurthy T, et al. Clinical profile of acute diarrhoea cases infected with the new epidemic strain of *Vibrio cholerae* O139: designation of the disease as cholera. *J Infect.* 1993; 27(1):11–5. PMID: [8370939](#)
2. Kaper JB, Morris JG Jr., Levine MM. Cholera. *Clin Microbiol Rev.* 1995; 8(1):48–86. PMID: [7704895](#)
3. Moore S, Thomson N, Mutreja A, Piarroux R. Widespread epidemic cholera caused by a restricted subset of *Vibrio cholerae* clones. *Clin Microbiol Infect.* 2014; 20(5):373–9. doi: [10.1111/1469-0691.12610](#) PMID: [24575898](#)
4. Yamai S, Okitsu T, Shimada T, Katsube Y. [Distribution of serogroups of *Vibrio cholerae* non-O1 non-O139 with specific reference to their ability to produce cholera toxin, and addition of novel serogroups]. *Kansenshogaku Zasshi.* 1997; 71(10):1037–45. PMID: [9394556](#)
5. Dalsgaard A, Forslund A, Bodhidatta L, Serichantalergs O, Pitarangsi C, Pang L, et al. A high proportion of *Vibrio cholerae* strains isolated from children with diarrhoea in Bangkok, Thailand are multiple antibiotic resistant and belong to heterogenous non-O1, non-O139 O-serotypes. *Epidemiol Infect.* 1999; 122(2):217–26. PMID: [10355785](#)
6. Onifade TJ, Hutchinson R, Van Zile K, Bodager D, Baker R, Blackmore C. Toxin producing *Vibrio cholerae* O75 outbreak, United States, March to April 2011. *Euro Surveill.* 2011; 16(20):19870. PMID: [21616048](#)
7. Chatterjee S, Ghosh K, Raychoudhuri A, Chowdhury G, Bhattacharya MK, Mukhopadhyay AK, et al. Incidence, virulence factors, and clonality among clinical strains of non-O1, non-O139 *Vibrio cholerae* isolates from hospitalized diarrheal patients in Kolkata, India. *J Clin Microbiol.* 2009; 47(4):1087–95. doi: [10.1128/JCM.02026-08](#) PMID: [19158257](#)
8. Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. *Lancet.* 2012; 379(9835):2466–76. doi: [10.1016/S0140-6736\(12\)60436-X](#) PMID: [22748592](#)
9. Devault AM, Golding GB, Waglechner N, Enk JM, Kuch M, Tien JH, et al. Second-pandemic strain of *Vibrio cholerae* from the Philadelphia cholera outbreak of 1849. *N Engl J Med.* 2014; 370(4):334–40. doi: [10.1056/NEJMoa1308663](#) PMID: [24401020](#)
10. Cho YJ, Yi H, Lee JH, Kim DW, Chun J. Genomic evolution of *Vibrio cholerae*. *Curr Opin Microbiol.* 2010; 13(5):646–51. doi: [10.1016/j.mib.2010.08.007](#) PMID: [20851041](#)

11. Chun J, Grim CJ, Hasan NA, Lee JH, Choi SY, Haley BJ, et al. Comparative genomics reveals mechanism for short-term and long-term clonal transitions in pandemic *Vibrio cholerae*. *Proc Natl Acad Sci U S A*. 2009; 106(36):15442–7. doi: [10.1073/pnas.0907787106](https://doi.org/10.1073/pnas.0907787106) PMID: [19720995](https://pubmed.ncbi.nlm.nih.gov/19720995/)
12. Mutreja A, Kim DW, Thomson NR, Connor TR, Lee JH, Kariuki S, et al. Evidence for several waves of global transmission in the seventh cholera pandemic. *Nature*. 2011; 477(7365):462–5. doi: [10.1038/nature10392](https://doi.org/10.1038/nature10392) PMID: [21866102](https://pubmed.ncbi.nlm.nih.gov/21866102/)
13. Chin CS, Sorenson J, Harris JB, Robins WP, Charles RC, Jean-Charles RR, et al. The origin of the Haitian cholera outbreak strain. *N Engl J Med*. 2011; 364(1):33–42. doi: [10.1056/NEJMoa1012928](https://doi.org/10.1056/NEJMoa1012928) PMID: [21142692](https://pubmed.ncbi.nlm.nih.gov/21142692/)
14. Hendriksen RS, Price LB, Schupp JM, Gillece JD, Kaas RS, Engelthaler DM, et al. Population genetics of *Vibrio cholerae* from Nepal in 2010: evidence on the origin of the Haitian outbreak. *MBio*. 2011; 2(4): e00157–11. doi: [10.1128/mBio.00157-11](https://doi.org/10.1128/mBio.00157-11) PMID: [21862630](https://pubmed.ncbi.nlm.nih.gov/21862630/)
15. Albert MJ, Siddique AK, Islam MS, Faruque AS, Ansaruzzaman M, Faruque SM, et al. Large outbreak of clinical cholera due to *Vibrio cholerae* non-O1 in Bangladesh. *Lancet*. 1993; 341(8846):704. PMID: [8095621](https://pubmed.ncbi.nlm.nih.gov/8095621/)
16. Nair GB, Faruque SM, Bhuiyan NA, Kamruzzaman M, Siddique AK, Sack DA. New variants of *Vibrio cholerae* O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. *J Clin Microbiol*. 2002; 40(9):3296–9. doi: [10.1128/JCM.40.9.3296-3299.2002](https://doi.org/10.1128/JCM.40.9.3296-3299.2002) PMID: [12202569](https://pubmed.ncbi.nlm.nih.gov/12202569/)
17. Safa A, Sultana J, Dac Cam P, Mwansa JC, Kong RY. *Vibrio cholerae* O1 hybrid El Tor strains, Asia and Africa. *Emerg Infect Dis*. 2008; 14(6):987–8. doi: [10.3201/eid1406.080129](https://doi.org/10.3201/eid1406.080129) PMID: [18507925](https://pubmed.ncbi.nlm.nih.gov/18507925/)
18. Na-Ubol M, Srimanote P, Chongsa-Nguan M, Indrawattana N, Sookrung N, Tapchaisri P, et al. Hybrid & El Tor variant biotypes of *Vibrio cholerae* O1 in Thailand. *Indian J Med Res*. 2011; 133:387–94. PMID: [21537091](https://pubmed.ncbi.nlm.nih.gov/21537091/)
19. Dixit SM, Johura FT, Manandhar S, Sadique A, Rajbhandari RM, Mannan SB, et al. Cholera outbreaks (2012) in three districts of Nepal reveal clonal transmission of multi-drug resistant *Vibrio cholerae* O1. *BMC Infect Dis*. 2014; 14:392. doi: [10.1186/1471-2334-14-392](https://doi.org/10.1186/1471-2334-14-392) PMID: [25022982](https://pubmed.ncbi.nlm.nih.gov/25022982/)
20. Global Health Observatory (GHO) data [database on the Internet]. World Health Organization. 2014. Available from: http://www.who.int/gho/epidemic_diseases/cholera/cases_text/en/.
21. Kirn TJ, Lafferty MJ, Sandoe CM, Taylor RK. Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by *Vibrio cholerae*. *Mol Microbiol*. 2000; 35(4):896–910. PMID: [10692166](https://pubmed.ncbi.nlm.nih.gov/10692166/)
22. Waldor MK, Mekalanos JJ. Lysogenic conversion by a filamentous phage encoding cholera toxin. *Science*. 1996; 272(5270):1910–4. PMID: [8658163](https://pubmed.ncbi.nlm.nih.gov/8658163/)
23. Rivera IN, Chun J, Huq A, Sack RB, Colwell RR. Genotypes associated with virulence in environmental isolates of *Vibrio cholerae*. *Appl Environ Microbiol*. 2001; 67(6):2421–9. doi: [10.1128/AEM.67.6.2421-2429.2001](https://doi.org/10.1128/AEM.67.6.2421-2429.2001) PMID: [11375146](https://pubmed.ncbi.nlm.nih.gov/11375146/)
24. Singh DV, Matte MH, Matte GR, Jiang S, Sabeena F, Shukla BN, et al. Molecular analysis of *Vibrio cholerae* O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates. *Appl Environ Microbiol*. 2001; 67(2):910–21. doi: [10.1128/AEM.67.2.910-921.2001](https://doi.org/10.1128/AEM.67.2.910-921.2001) PMID: [11157262](https://pubmed.ncbi.nlm.nih.gov/11157262/)
25. Luo Y, Ye J, Jin D, Ding G, Zhang Z, Mei L, et al. Molecular analysis of non-O1/non-O139 *Vibrio cholerae* isolated from hospitalised patients in China. *BMC Microbiol*. 2013; 13:52. doi: [10.1186/1471-2180-13-52](https://doi.org/10.1186/1471-2180-13-52) PMID: [23497008](https://pubmed.ncbi.nlm.nih.gov/23497008/)
26. Epidemiology Bo. Annual epidemiological surveillance report. In: Department of Disease Control MoPH, editor. Nonthaburi, Thailand: Bureau of Epidemiology; 2014.
27. Chomvarin C, Johura FT, Mannan SB, Jumroenjit W, Kanoktippornchai B, Tangkanakul W, et al. Drug response and genetic properties of *Vibrio cholerae* associated with endemic cholera in north-eastern Thailand, 2003–2011. *J Med Microbiol*. 2013; 62(Pt 4):599–609. doi: [10.1099/jmm.0.053801-0](https://doi.org/10.1099/jmm.0.053801-0) PMID: [23319310](https://pubmed.ncbi.nlm.nih.gov/23319310/)
28. Wozniak RA, Fouts DE, Spagnoletti M, Colombo MM, Ceccarelli D, Garriss G, et al. Comparative ICE genomics: insights into the evolution of the SXT/R391 family of ICEs. *PLoS Genet*. 2009; 5(12): e1000786. doi: [10.1371/journal.pgen.1000786](https://doi.org/10.1371/journal.pgen.1000786) PMID: [20041216](https://pubmed.ncbi.nlm.nih.gov/20041216/)
29. Alam M, Sultana M, Nair GB, Siddique AK, Hasan NA, Sack RB, et al. Viable but nonculturable *Vibrio cholerae* O1 in biofilms in the aquatic environment and their role in cholera transmission. *Proc Natl Acad Sci U S A*. 2007; 104(45):17801–6. doi: [10.1073/pnas.0705599104](https://doi.org/10.1073/pnas.0705599104) PMID: [17968017](https://pubmed.ncbi.nlm.nih.gov/17968017/)
30. Bhumiratana A, Siriphap A, Khamsuwan N, Borthong J, Chonsin K, Suthieikul O. O Serogroup-Specific Touchdown-Multiplex Polymerase Chain Reaction for Detection and Identification of *Vibrio cholerae*

- O1, O139, and Non-O1/Non-O139. *Biochem Res Int*. 2014; 2014:295421. doi: [10.1155/2014/295421](https://doi.org/10.1155/2014/295421) PMID: [25614837](https://pubmed.ncbi.nlm.nih.gov/25614837/)
31. WHO. Manual for laboratory investigations of acute enteric infections. WHO document. 1987.
 32. Kaas RS, Ngandjio A, Nzouankeu A, Siriphap A, Fonkoua MC, Aarestrup FM, et al. The Lake Chad Basin, an Isolated and Persistent Reservoir of *Vibrio cholerae* O1: A Genomic Insight into the Outbreak in Cameroon, 2010. *PLoS One*. 2016; 11(5):e0155691. doi: [10.1371/journal.pone.0155691](https://doi.org/10.1371/journal.pone.0155691) PMID: [27191718](https://pubmed.ncbi.nlm.nih.gov/27191718/)
 33. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
 34. Zankari E, Hasman H, Kaas RS, Seyfarth AM, Agerso Y, Lund O, et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. *J Antimicrob Chemother*. 2013; 68(4):771–7. doi: [10.1093/jac/dks496](https://doi.org/10.1093/jac/dks496) PMID: [23233485](https://pubmed.ncbi.nlm.nih.gov/23233485/)
 35. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. *J Clin Microbiol*. 2012; 50(4):1355–61. doi: [10.1128/JCM.06094-11](https://doi.org/10.1128/JCM.06094-11) PMID: [22238442](https://pubmed.ncbi.nlm.nih.gov/22238442/)
 36. Octavia S, Salim A, Kurniawan J, Lam C, Leung Q, Ahsan S, et al. Population structure and evolution of non-O1/non-O139 *Vibrio cholerae* by multilocus sequence typing. *PLoS One*. 2013; 8(6):e65342. doi: [10.1371/journal.pone.0065342](https://doi.org/10.1371/journal.pone.0065342) PMID: [23776471](https://pubmed.ncbi.nlm.nih.gov/23776471/)
 37. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res*. 2004; 32(5):1792–7. doi: [10.1093/nar/gkh340](https://doi.org/10.1093/nar/gkh340) PMID: [15034147](https://pubmed.ncbi.nlm.nih.gov/15034147/)
 38. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. *Mol Biol Evol*. 2011; 28(10):2731–9. doi: [10.1093/molbev/msr121](https://doi.org/10.1093/molbev/msr121) PMID: [21546353](https://pubmed.ncbi.nlm.nih.gov/21546353/)
 39. Hallin PF, Binnewies TT, Ussery DW. The genome BLAST atlas—a GeneWiz extension for visualization of whole-genome homology. *Mol Biosyst*. 2008; 4(5):363–71. doi: [10.1039/b717118h](https://doi.org/10.1039/b717118h) PMID: [18414733](https://pubmed.ncbi.nlm.nih.gov/18414733/)
 40. Hoge CW, Bodhidatta L, Echeverria P, Deesuan M, Kitporka P. Epidemiologic study of *Vibrio cholerae* O1 and O139 in Thailand: at the advancing edge of the eighth pandemic. *Am J Epidemiol*. 1996; 143(3):263–8. PMID: [8561160](https://pubmed.ncbi.nlm.nih.gov/8561160/)
 41. Bhattacharya D, Dey S, Pazhani GP, Ramamurthy T, Parande MV, Kholkute SD, et al. *Vibrio cholerae* O1 El Tor variant and emergence of Haitian *ctxB* variant in the strains isolated from South India. *Med Microbiol Immunol*. 2016; 205(2):195–200. doi: [10.1007/s00430-015-0433-y](https://doi.org/10.1007/s00430-015-0433-y) PMID: [26337047](https://pubmed.ncbi.nlm.nih.gov/26337047/)
 42. Safa A, Bhuyian NA, Nusrin S, Ansaruzzaman M, Alam M, Hamabata T, et al. Genetic characteristics of Matlab variants of *Vibrio cholerae* O1 that are hybrids between classical and El Tor biotypes. *J Med Microbiol*. 2006; 55(Pt 11):1563–9. doi: [10.1099/jmm.0.46689-0](https://doi.org/10.1099/jmm.0.46689-0) PMID: [17030917](https://pubmed.ncbi.nlm.nih.gov/17030917/)
 43. Safa A, Bhuyian NA, Murphy D, Bates J, Nusrin S, Kong RY, et al. Multilocus genetic analysis reveals that the Australian strains of *Vibrio cholerae* O1 are similar to the pre-seventh pandemic strains of the El Tor biotype. *J Med Microbiol*. 2009; 58(Pt 1):105–11. doi: [10.1099/jmm.0.004333-0](https://doi.org/10.1099/jmm.0.004333-0) PMID: [19074660](https://pubmed.ncbi.nlm.nih.gov/19074660/)
 44. Preeprem S, Mittraparp-arthorn P, Bhoopong P, Vuddhakul V. Isolation and characterization of *Vibrio cholerae* isolates from seafood in Hat Yai City, Songkhla, Thailand. *Foodborne Pathog Dis*. 2014; 11(11):881–6. doi: [10.1089/fpd.2014.1772](https://doi.org/10.1089/fpd.2014.1772) PMID: [25188839](https://pubmed.ncbi.nlm.nih.gov/25188839/)
 45. Tapchaisri P, Na-Ubol M, Tiyasuttipan W, Chaiyaroj SC, Yamasaki S, Wongsarot J, et al. Molecular typing of *Vibrio cholerae* O1 isolates from Thailand by pulsed-field gel electrophoresis. *J Health Popul Nutr*. 2008; 26(1):79–87. PMID: [18637531](https://pubmed.ncbi.nlm.nih.gov/18637531/)
 46. Tabtieng R, Wattanasri S, Echeverria P, Seriwatana J, Bodhidatta L, Chatkaemorakot A, et al. An epidemic of *Vibrio cholerae* el tor Inaba resistant to several antibiotics with a conjugative group C plasmid coding for type II dihydrofolate reductase in Thailand. *Am J Trop Med Hyg*. 1989; 41(6):680–6. PMID: [2641646](https://pubmed.ncbi.nlm.nih.gov/2641646/)
 47. Ghosh-Banerjee J, Senoh M, Takahashi T, Hamabata T, Barman S, Koley H, et al. Cholera toxin production by the El Tor variant of *Vibrio cholerae* O1 compared to prototype El Tor and classical biotypes. *J Clin Microbiol*. 2010; 48(11):4283–6. doi: [10.1128/JCM.00799-10](https://doi.org/10.1128/JCM.00799-10) PMID: [20810767](https://pubmed.ncbi.nlm.nih.gov/20810767/)
 48. Kumar P, Jain M, Goel AK, Bhadauria S, Sharma SK, Kamboj DV, et al. A large cholera outbreak due to a new cholera toxin variant of the *Vibrio cholerae* O1 El Tor biotype in Orissa, Eastern India. *J Med Microbiol*. 2009; 58(Pt 2):234–8. doi: [10.1099/jmm.0.002089-0](https://doi.org/10.1099/jmm.0.002089-0) PMID: [19141742](https://pubmed.ncbi.nlm.nih.gov/19141742/)
 49. Kim EJ, Lee D, Moon SH, Lee CH, Kim SJ, Lee JH, et al. Molecular insights into the evolutionary pathway of *Vibrio cholerae* O1 atypical El Tor variants. *PLoS Pathog*. 2014; 10(9):e1004384. doi: [10.1371/journal.ppat.1004384](https://doi.org/10.1371/journal.ppat.1004384) PMID: [25233006](https://pubmed.ncbi.nlm.nih.gov/25233006/)
 50. Faruque SM, Chowdhury N, Kamruzzaman M, Dziejman M, Rahman MH, Sack DA, et al. Genetic diversity and virulence potential of environmental *Vibrio cholerae* population in a cholera-endemic area. *Proc Natl Acad Sci U S A*. 2004; 101(7):2123–8. doi: [10.1073/pnas.0308485100](https://doi.org/10.1073/pnas.0308485100) PMID: [14766976](https://pubmed.ncbi.nlm.nih.gov/14766976/)

51. Li X, Wang D, Li B, Zhou H, Liang S, Ke C, et al. Characterization of environmental *Vibrio cholerae* serogroups O1 and O139 in the Pearl River Estuary, China. *Can J Microbiol*. 2016; 62(2):139–47. doi: [10.1139/cjm-2015-0443](https://doi.org/10.1139/cjm-2015-0443) PMID: [26674584](https://pubmed.ncbi.nlm.nih.gov/26674584/)
52. Okada K, Roobthaisong A, Swaddiwudhipong W, Hamada S, Chantaroj S. *Vibrio cholerae* O1 isolate with novel genetic background, Thailand-Myanmar. *Emerg Infect Dis*. 2013; 19(6):1015–7. doi: [10.3201/eid1906.120345](https://doi.org/10.3201/eid1906.120345) PMID: [23735934](https://pubmed.ncbi.nlm.nih.gov/23735934/)
53. Karaolis DK, Somara S, Maneval DR Jr., Johnson JA, Kaper JB. A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria. *Nature*. 1999; 399(6734):375–9. doi: [10.1038/20715](https://doi.org/10.1038/20715) PMID: [10360577](https://pubmed.ncbi.nlm.nih.gov/10360577/)
54. Faruque SM, Mekalanos JJ. Pathogenicity islands and phages in *Vibrio cholerae* evolution. *Trends Microbiol*. 2003; 11(11):505–10. PMID: [14607067](https://pubmed.ncbi.nlm.nih.gov/14607067/)
55. Awasthi SP, Asakura M, Chowdhury N, Neogi SB, Hinenoya A, Golbar HM, et al. Novel cholix toxin variants, ADP-ribosylating toxins in *Vibrio cholerae* non-O1/non-O139 strains, and their pathogenicity. *Infect Immun*. 2013; 81(2):531–41. doi: [10.1128/IAI.00982-12](https://doi.org/10.1128/IAI.00982-12) PMID: [23230295](https://pubmed.ncbi.nlm.nih.gov/23230295/)
56. Sjolund-Karlsson M, Reimer A, Folster JP, Walker M, Dahourou GA, Batra DG, et al. Drug-resistance mechanisms in *Vibrio cholerae* O1 outbreak strain, Haiti, 2010. *Emerg Infect Dis*. 2011; 17(11):2151–4. doi: [10.3201/eid1711.110720](https://doi.org/10.3201/eid1711.110720) PMID: [22099122](https://pubmed.ncbi.nlm.nih.gov/22099122/)
57. Pang B, Du P, Zhou Z, Diao B, Cui Z, Zhou H, et al. The Transmission and Antibiotic Resistance Variation in a Multiple Drug Resistance Clade of *Vibrio cholerae* Circulating in Multiple Countries in Asia. *PLoS One*. 2016; 11(3):e0149742. doi: [10.1371/journal.pone.0149742](https://doi.org/10.1371/journal.pone.0149742) PMID: [26930352](https://pubmed.ncbi.nlm.nih.gov/26930352/)
58. Kitaoka M, Miyata ST, Unterweger D, Pukatzki S. Antibiotic resistance mechanisms of *Vibrio cholerae*. *J Med Microbiol*. 2011; 60(Pt 4):397–407. doi: [10.1099/jmm.0.023051-0](https://doi.org/10.1099/jmm.0.023051-0) PMID: [21252269](https://pubmed.ncbi.nlm.nih.gov/21252269/)
59. Marin MA, Thompson CC, Freitas FS, Fonseca EL, Aboderin AO, Zailani SB, et al. Cholera outbreaks in Nigeria are associated with multidrug resistant atypical El Tor and non-O1/non-O139 *Vibrio cholerae*. *PLoS Negl Trop Dis*. 2013; 7(2):e2049. doi: [10.1371/journal.pntd.0002049](https://doi.org/10.1371/journal.pntd.0002049) PMID: [23459673](https://pubmed.ncbi.nlm.nih.gov/23459673/)
60. Supawat K, Huttayananont S, Sawanpanyalert P, Aswapokee N, Moosikapun P. Antimicrobial resistance surveillance of *Vibrio cholerae* in Thailand from 2000 to 2004. *J Med Assoc Thai*. 2009; 92 Suppl 4:S82–6.
61. Kumar P, Mishra DK, Deshmukh DG, Jain M, Zade AM, Ingole KV, et al. Haitian variant *ctxB* producing *Vibrio cholerae* O1 with reduced susceptibility to ciprofloxacin is persistent in Yavatmal, Maharashtra, India, after causing a cholera outbreak. *Clin Microbiol Infect*. 2014; 20(5):O292–3. doi: [10.1111/1469-0691.12393](https://doi.org/10.1111/1469-0691.12393) PMID: [24102849](https://pubmed.ncbi.nlm.nih.gov/24102849/)
62. Waldor MK, Tschape H, Mekalanos JJ. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in *Vibrio cholerae* O139. *J Bacteriol*. 1996; 178(14):4157–65. PMID: [8763944](https://pubmed.ncbi.nlm.nih.gov/8763944/)
63. Hochhut B, Waldor MK. Site-specific integration of the conjugal *Vibrio cholerae* SXT element into *prfC*. *Mol Microbiol*. 1999; 32(1):99–110. PMID: [10216863](https://pubmed.ncbi.nlm.nih.gov/10216863/)
64. Abd El Ghany M, Chander J, Mutreja A, Rashid M, Hill-Cawthorne GA, Ali S, et al. The population structure of *Vibrio cholerae* from the Chandigarh Region of Northern India. *PLoS Negl Trop Dis*. 2014; 8(7):e2981. doi: [10.1371/journal.pntd.0002981](https://doi.org/10.1371/journal.pntd.0002981) PMID: [25058483](https://pubmed.ncbi.nlm.nih.gov/25058483/)